Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13413087 | 1.00 | PTGS1 (0.32) | PTGS1PTGS2 | |
| SCHEMBL12454158 | 0.87 | — | — | |
| SCHEMBL19416688 | 0.83 | PTGS1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL10476740 | 0.83 | PTGS1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL10195944 | 0.83 | PTGS1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL3437283 | 0.83 | PTGS1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL765228 | 0.83 | PTGS1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL12952136 | 0.82 | PPM1B (0.32) | — | |
| SCHEMBL216588 | 0.79 | — | — | |
| SCHEMBL5821287 | 0.76 | PPM1B (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | PTGS1 854/4885PTGS2 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.